Table 2.
List of annotated significantly altered metabolomic features.
| Compound Class | Compound Name | RT|m/z | Regulation (Up/Down) a | Fold-Change b | p-Value c |
|---|---|---|---|---|---|
| 2-Arylbenzofuran flavonoids | Lixivaptan | 6.83|472.29 | DOWN | 0.39 | 6.0 × 10−5 |
| Alkyl halides | Perfluorododecanoic acid | 6.41|613.36 | UP | 1.85 | 7.6 × 10−9 |
| Benzene & substituted derivatives | 1-Piperazinecarboxylic acid, 4-((3,4-dichlorophenyl)acetyl)-3-(1-pyrrolidinylmethyl)-, methyl ester, (3R)- | 10.18|413.33 | DOWN | 0.64 | 2.1 × 10−6 |
| D-Vacciniin | 4.57|283.08 | UP | 1.86 | 1.3 × 10−5 | |
| Carboxylic acids & derivatives | S-Cysteinosuccinic acid | 4.92|236.09 | UP | 1.84 | 8.3 × 10−10 |
| N-Acetyl-L-phenylalanine | 4.60|208.13 | UP | 0.51 | 5.9 × 10−6 | |
| Diisodityrosine | 5.07|716.85 | UP | 2.06 | 3.1 × 10−7 | |
| Coumarans | Carbosulfan | 4.84|379.16 | UP | 4.00 | 2.5 × 10−9 |
| Fatty Acyls | 15-Palmitoylsolamin | 4.33|801.42 | UP | 2.63 | 2.7 × 10−4 |
| Stearoyllactic acid | 9.41|355.29 | DOWN | 0.59 | 3.5 × 10−7 | |
| 4,7,10,13-Hexadecatetraenoate | 10.72|251.20 | UP | 0.60 | 4.1 × 10−5 | |
| Flavonoids | Eriodictin | 5.70|433.21 | UP | 4.81 | 5.2 × 10−11 |
| 7-Chloro-3,4′,5,6,8-pentamethoxyflavone | 5.24|405.18 | UP | 4.58 | 5.3 × 10−10 | |
| Indoles & derivatives | Bismurrayafoline E | 4.59|723.37 | UP | 1.99 | 5.4 × 10−7 |
| Indolepyruvate | 4.84|204.10 | UP | 1.62 | 8.5 × 10−4 | |
| Organooxygen compounds | Salicyluric beta-D-glucuronide | 3.90|370.08 | UP | 9.00 | 1.1 × 10−15 |
| Aldehydo-N-acetyl-D-glucosamine | 5.38|219.95 | UP | 5.37 | 3.8 × 10−10 | |
| N-Acetylgalactosamine 4-sulphate | 4.99|302.20 | UP | 0.64 | 2.9 × 10−4 | |
| alpha-Furyl methyl diketone | 5.38|137.02 | UP | 7.18 | 3.2 × 10−10 | |
| Oxazinanes | Molsidomine | 8.02|241.18 | DOWN | 0.53 | 3.9 × 10−10 |
| Prenol lipids | 15-cis-Phytoene | 5.34|543.28 | UP | 2.18 | 6.1 × 10−10 |
| ′-6′-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin | 5.08|631.35 | UP | 1.54 | 9.4 × 10−5 | |
| Pyrimidine nucleoside’ | 2′,2′-Difluorodeoxyuridine | 4.66|264.01 | UP | 5.39 | 6.0 × 10−13 |
| Pyrroles | O-Hydroxyatorvastatin | 7.45|573.24 | UP | 2.98 | 1.6 × 10−12 |
| Steroids & steroid derivatives | Etiocholanolone | 10.39|241.18 | UP | 0.57 | 1.6 × 10−5 |
| Tetrapyrroles & derivatives | L-Urobilin | 5.73|593.34 | UP | 3.39 | 5.0 × 10−4 |
a “UP” denotes presence of higher amounts of the analyte (i.e., up-regulated) in AMI patients as compared to healthy volunteers, while “DOWN” denotes the presence of lower amounts of the analyte (i.e., down-regulated) in AMI patients. b Fold-change was calculated by dividing the mean peak area of analyte in AMI patients over the mean peak area of analyte in healthy volunteers. A fold-change > 1 also implies up-regulation in AMI patients, while a fold change < 1 implies down-regulation. c p-value was FDR-adjusted.